A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (CONVERGE)
Last Updated May 31, 2025
Want to learn how to participate in this trial?
90301900NSC2001
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 2 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
CONDITIONS
- Carcinoma, Non-Small-Cell Lung
ELIGIBILITY
Inclusion Criteria:
* Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and p
DETAILS
LOCATIONS
| Country (1) | City or Province (7) | Status |
| United States | Orlando Orlando Health Cancer Institute |
RECRUITING
|
| United States | Pinehurst FirstHealth of the Carolinas |
RECRUITING
|
| United States | Philadelphia University of Pennsylvania |
RECRUITING
|
| United States | New York NYU Langone Health |
RECRUITING
|
| United States | Farmington University of Connecticut Health Center |
RECRUITING
|
| United States | Chapel Hill University of North Carolina at Chapel Hill |
RECRUITING
|
| United States | Burlington University of Vermont Medical Center |
RECRUITING
|
28.53834, -81.37924
35.19543, -79.46948
39.95233, -75.16379
40.71427, -74.00597
41.71982, -72.83204
35.9132, -79.05584
44.47588, -73.21207
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.